Ken Fisher Chinook Therapeutics, Inc. Transaction History

Fisher Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 12, 2023	BUY	$18.66 - $38.58 $425,821 - $880,395	22,820 New	22,820 $876,000
Q2 2023 Aug 08, 2023	SELL	$18.66 - $38.58 $244,128 - $504,742	-13,083 Reduced 36.44%	22,820 $876,000
Q1 2023 Dec 12, 2023	BUY	$21.53 - $26.8 $772,991 - $962,200	35,903 New	35,903 $831,000
Q1 2023 May 01, 2023	SELL	$21.53 - $26.8 $174,393 - $217,080	-8,100 Reduced 18.41%	35,903 $831,000
Q4 2022 Feb 03, 2023	SELL	$18.63 - $27.35 $130,484 - $191,559	-7,004 Reduced 13.73%	44,003 $1.15 Million
Q3 2022 Nov 08, 2022	BUY	$17.51 - $23.37 $893,132 - $1.19 Million	51,007 New	51,007 $1 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.